Premium
Inhibition of Angiotensin‐Converting Enzyme with Libenzapril in Normotensive Males
Author(s) -
Morgan John M.,
Piraino Anthony J.,
Saris Steven D.,
Graham Camilla S.,
Hirschhorn William L.,
Kochak Gregory M.,
Choi R. Les
Publication year - 1994
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1994.tb04729.x
Subject(s) - angiotensin converting enzyme , pharmacology , renin–angiotensin system , enzyme , endocrinology , medicine , chemistry , blood pressure , biochemistry
The effect of intravenous (IV) libenzapril was studied in six healthy males by administering IV angiotensin I (AI) administered in stepwise increments of 20 ng/kg/5 min until the subjects' systolic blood pressure (SBP) had increased 20–30 mm Hg above baseline. The mean baseline infusion of 63 ng/kg/5 min resulted in a significant ( P < 0.05) increase in the ratio of AII to AI plasma levels from 0.52 ± 0.46 to 7.92 ± 4.48 and a SBP increase of 120 ± 7.1 to 147 ± 5.6. Within 15 minutes of starting the 1‐mg infusion of libenzapril over 1.5 hours, the AII/AI ratio decreased to baseline values, and the SBP had returned to baseline in 1 hour. Repeat AI challenges at 3.5 and 5 hours postdose did not increase SBP significantly. Even the 6.5‐hour challenge demonstrated only a slight increase in SBP, with an AII/AI ratio of 0.26. At 24 hours, SBP was only 40% of the baseline response, demonstrating that libenzapril is a potent long‐acting ACE inhibitor .